GP advice regarding RSV vaccine and mAb

The following update has been sent out to GPs today by NSW Health regarding respiratory syncytial virus (RSV).

This includes:

• The current recommendations for monoclonal antibody (mAb) eligibility and access for vulnerable babies and under the

NSW Health RSV vulnerable babies program

• Arexvy vaccine for > 60 years (available on the private market only) and current ATAGI recommendations

Statement on the Clinical use of Zoster vaccine in older adults in Australia (health.gov.au)